Eli Lilly seeks EUA from FDA for its SARS-CoV-2 mAbs

By The Science Advisory Board staff writers

October 7, 2020 -- Eli Lilly submitted an emergency use authorization (EUA) request from the U.S. Food and Drug Administration (FDA) for its SARS-CoV-2 monoclonal antibodies (mAbs).

Data show that both monotherapy and combination therapy may be effective to treat COVID-19 in patients with a high risk for serious outcomes, according to the company. It plans to make these therapies broadly available to patients.

Lilly anticipates it could supply up to 1 million doses of 700 mg of LY-CoV555 monotherapy in the last quarter of 2020, with 100,000 available in October. The company anticipates it will have 50,000 doses of its combination therapy available in the fourth quarter of 2020. The supply of combination therapy will increase substantially in the beginning of 2021, according to the firm.

Amgen, Eli Lilly to scale up manufacturing of COVID-19 antibody therapies
Eli Lilly and Amgen will collaborate on global antibody manufacturing to significantly increase the supply capacity of Lilly's potential COVID-19 therapies.
Eli Lilly rolls out early COVID-19 antibody trial data
Eli Lilly released early data from a phase II clinical trial that explored the use of the neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting.
Eli Lilly, Innovent expand immuno-oncology licensing
Eli Lilly and Innovent Biologics have agreed to a global expansion of their strategic alliance for Tyvyt (sintilimab injection), an anti-programmed cell...
Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter